South San Francisco, California — September 16, 2025 — Leads & Copy — Alector, Inc. (Nasdaq: ALEC) will host a virtual event to discuss its progranulin (PGRN) franchise and Alector Brain Carrier (ABC)–enabled programs. The event will include a review of latozinemab, in a Phase 3 trial for frontotemporal dementia due to a GRN gene mutation, and AL101, in a Phase 2 trial for early Alzheimer’s disease (AD). The company will present preclinical data on lead candidates for its ABC–enabled programs, including its brain-penetrant anti-amyloid beta antibody program for AD, and its brain-penetrant engineered GCase-enzyme replacement therapy for Parkinson’s disease. The event will also highlight progress in Alector’s ABC-enabled siRNA programs.
The webinar, “Alector R&D Briefing: A Review of Our PGRN Franchise and Brain Carrier Programs” is scheduled for Monday, September 22, 2025, from 12:00 to 1:30 pm EDT. A live question and answer session will follow the formal presentation. To access the live webcast of this event, please register here, or visit “Events and Presentations” in the “Investors” section of the Alector website.
Alector is focused on developing therapies to counteract the progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function.
Katie Hogan, Alector, 202-549-0557, katie.hogan@alector.com
Source: Alector, Inc.
